What the FDA labels say about taking them together
Dabigatran and sodium zirconium cyclosilicate
Sodium zirconium cyclosilicate's FDA label of February 8, 2024 names dabigatran in its drug interactions section; the dabigatran labels PlainMeds reads (2) do not name sodium zirconium cyclosilicate. The sodium zirconium cyclosilicate label: “However, there was an increase in systemic exposure to weak acids such as furosemide and atorvastatin, and a decrease in systemic exposure to weak bases such as dabigatran when co-administered with LOKELMA, as shown in …”
Check it at the source: the dabigatran FDA label on DailyMed (effective June 25, 2025, Boehringer Ingelheim Pharmaceuticals Inc.); the sodium zirconium cyclosilicate FDA label on DailyMed (effective February 8, 2024, AstraZeneca Pharmaceuticals LP).
What does the dabigatran label say about sodium zirconium cyclosilicate?
Dabigatran's label (effective June 25, 2025) and its 1 other brand-application label do not name sodium zirconium cyclosilicate in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Pradaxa), Boehringer Ingelheim Pharmaceuticals Inc., effective June 25, 2025 (SPL set ba74e3cd-b06f-4145-b284-5fd6b84ff3c9), via openFDA; the full label on DailyMed
What does the sodium zirconium cyclosilicate label say about dabigatran?
Sodium zirconium cyclosilicate label, drug interactionsHowever, there was an increase in systemic exposure to weak acids such as furosemide and atorvastatin, and a decrease in systemic exposure to weak bases such as dabigatran when co-administered with LOKELMA, as shown in Figure 2.
Source: FDA drug label (LOKELMA), AstraZeneca Pharmaceuticals LP, effective February 8, 2024 (SPL set 90bf8e28-748d-4e4b-a19f-9cf483370eff), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Dabigatran | Sodium zirconium cyclosilicate | |
|---|---|---|
| Labeled for | Atrial fibrillation, Blood clots (DVT and PE), Stroke prevention | n/a |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.795 per capsule 150 mg capsule | $28.33 per packet 10 gram powder packet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once